ICON plc’s ICLR focus on Patient Access & Engagement strategy and favorable CRO industry trends are major tailwinds. Strategic partnerships are an added positive. The stock carries a Zacks Rank #2 ...

ICON’s ICLR focus on Patient Access & Engagement strategy is a major tailwind along with partnerships and acquisitions. The stock carries a Zacks Rank #2 (Buy) currently. ICON is gaining from its ...

ICON plc’s ICLR focus on Patient Access & Engagement strategy and favorable CRO industry trends are major tailwinds. Strategic partnerships are an added plus. The stock carries a Zacks Rank #2 (Buy) ...

The company anticipates continued volatility in bookings due to customer caution and reprioritizations. Elevated cancellation rates are expected to persist throughout 2025. Guidance for 2025 reflects ...

On Wednesday, 04 June 2025, ICON PLC (NASDAQ:ICLR) presented at the 45th Annual William Blair Growth Stock Conference. CEO Steve Cutler outlined both the hurdles and opportunities facing the Contract ...

BALLERUP, Denmark & DUBLIN--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to ...